- Mithra grants exclusive license for vaginal contraception ring to Alvogen for commercialization in Russia
- Agreement follows MyringTM licenses closed with Mayne Pharma, Gynial and Adamed for the US, Austria and the Czech Republic, respectively
- Vaginal ring shall be manufactured at Mithra CDMO
Liège, Belgium, 16 March 2018, 05:45 PM – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced an exclusive license and supply agreement (LSA) with Alvogen for the commercialization in Russia of Mithra’s contraceptive vaginal ring product candidate made of ethylene vinyl acetate copolymers (EVA). Financial details of the agreement were not disclosed.